Skip to main content Skip to navigation
Purified Mouse Anti-ECA39
Product Details
Down Arrow Up Arrow


BD Transduction Laboratories™
Human (QC Testing)
Mouse IgG1
Human ECA39 aa. 213-335
Western blot (Routinely Tested), Immunofluorescence (Tested During Development)
43 kDa
250 µg/ml
AB_398799
Aqueous buffered solution containing BSA, glycerol, and ≤0.09% sodium azide.
RUO


Preparation And Storage

The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. Store undiluted at -20°C.

Product Notices

  1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
  2. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
  3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
  4. Source of all serum proteins is from USDA inspected abattoirs located in the United States.
611271 Rev. 1
Antibody Details
Down Arrow Up Arrow
51/ECA39

The c-myc oncogene is important in proliferation, differentiation, apoptosis, and malignant transformation. Products of myc oncogenes are transcription factors that bind to the DNA sequence, CACGTG, and regulate the expression of multiple target genes. Several myc target genes include ECA39, p53, ornithine decarboxylase (ODC), alpha-prothymosin, and Cdc25A. There is a high degree of identity among the mouse, human, and yeast ECA39 proteins. The myc recognition binding site of ECA39 is located 3' to the start site of transcription in the mouse and human genes, but this element is absent in the nematode and yeast. Additionally, the tissue specific expression of ECA39 during embryogenesis is similar between human and mouse. Disruption of the ECA39 gene in yeast results in an increased growth rate in comparison to wild type, such that G1 is shorter. Furthermore, ECA39 is expressed in c-myc induced tumors and displays significant homology to the prokaryotic branched-chain amino acid aminotransferase (BCAT). Thus, ECA39 may be involved in the regulation of the cell cycle, possibly at the G1 to S phase transition.

611271 Rev. 1
Format Details
Down Arrow Up Arrow
Purified
Tissue culture supernatant is purified by either protein A/G or affinity purification methods. Both methods yield antibody in solution that is free of most other soluble proteins, lipids, etc. This format provides pure antibody that is suitable for a number of downstream applications including: secondary labeling for flow cytometry or microscopy, ELISA, Western blot, etc.
Purified
611271 Rev.1
Citations & References
Down Arrow Up Arrow

Development References (4)

  1. Ben-Yosef T, Yanuka O, Benvenisty N. ECA39 is regulated by c-Myc in human and by a Jun/Fos homolog, Gcn4, in yeast. Oncogene. 1996; 13(9):1859-1866. (Biology). View Reference
  2. Ben-Yosef T, Yanuka O, Halle D, Benvenisty N. Involvement of Myc targets in c-myc and N-myc induced human tumors. Oncogene. 1998; 17(2):165-171. (Biology). View Reference
  3. Eden A, Simchen G, Benvenisty N. Two yeast homologs of ECA39, a target for c-Myc regulation, code for cytosolic and mitochondrial branched-chain amino acid aminotransferases. J Biol Chem. 1996; 271(34):20242-20245. (Biology). View Reference
  4. Schuldiner O, Eden A, Ben-Yosef T, Yanuka O, Simchen G, Benvenisty N. ECA39, a conserved gene regulated by c-Myc in mice, is involved in G1/S cell cycle regulation in yeast. 1996; 93(14):7143-7148. (Biology). View Reference
View All (4) View Less
611271 Rev. 1

Please refer to Support Documents for Quality Certificates


Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

Non-IVD products are For Research Use Only. Not for use in diagnostic or therapeutic procedures.

 

23-22940-00